Biology, medicine, and the technology extending human capability.
DeepMind's structure prediction tool has been used in 2 million research projects.
Semaglutide's primary patents expire between 2026 and 2031, opening the market to biosimilars.
Semaglutide and tirzepatide are showing strong efficacy against alcohol, nicotine, and opioid addiction in early trials.
After COVID mRNA vaccines, Moderna and Pfizer have completed Phase 3 trials for influenza with substantially better efficacy.
Altos Labs' first human trial data shows statistically significant improvement on biological age markers.
Vertex and CRISPR Therapeutics' Casgevy is now in the hands of 340 patients.